Regeneron Pharmaceuticals, Inc. (REGN)

840.14 -9.04 (-1.06%) At close: 04:00PM EST

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12,463

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman	7M	N/A	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman	6.59M	N/A	1960
Mr. Robert E. Landry Jr.	Executive VP of Finance & CFO	1.84M	11.1M	1964
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research	1.62M	19.39M	1959
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply	1.95M	45.28M	1973
Ms. Marion E. McCourt	Executive Vice President of Commercial	1.5M	4.25M	1960
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	N/A	N/A	N/A
Mr. Christopher R. Fenimore CPA	Senior VP, Head of Accounting & Controller	N/A	N/A	1971
Mr. Gerald Underwood	Senior Vice President of Technical Operations	N/A	N/A	N/A
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate governance

Regeneron Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.